Harsukh Parmar has been appointed as new member of the Scientific Advisory Board at ISD Immunotech.
“We are excited about the appointment of Dr. Parmar, an experienced leader in autoimmune disease who has insights into unmet needs in SLE and who comes with a solid track record of success advancing drug candidates through the drug development process and to market. His appointment to ISD Immunotech’s scientific advisory board provides us with more more industrial clinical experience in translational drug development, and ensures that we always have first-hand insights from both key markets, US and Europe,” says Tara Heitner, Chief Executive Officer, ISD Immunotech.
Read more: Personalized therapy for severe lupus
Dr. Parmar adds further expertise in medical innovation, translational drug development and clinical trials in systemic lupus erythematosus (SLE) and autoimmune disease and both a USA and European perspective to the company’s scientific advisory board. Parmar brings years of industry and clinical experience as he has worked for more than 24 years at Pfizer, Roche, AstraZeneca & Merck Kga and has transitioned more than 120 NME’s from Discovery into Development and Launch of several mega blockbusters in his previous roles.
He has also worked across several therapeutic areas including immunology, oncology, cardiology, respiratory, and neurology and transitioned numerous molecules into the SLE and autoimmune space. He chaired and lead the cross-functional Translational Medicine Leadership Team comprising of both discovery and development functions within AstraZeneca, Medimmune & Roche. He served for 7 years on the AZ global human exposures limit committee, responsible for transition of all new NME’s into man, children, and women of child bearing age and has served on all the major R & D governance committees at all his former companies (eg DRC, HELC, DOC etc). He has also chaired and been keynote speaker at more than 150 industry and academic conferences and has published extensively in a wide range of subjects and is cited in Marquis Who Who in the World since 1990 for his contributions to science and medicine.
”ISD Immunotech is an innovative new start-up on the Danish biotech scene. The company is led by a passionate and dedicated management team, board and SAB that has a unique entrepreneurial spirit and is based upon solid scientific research that can make an impact for lupus patients. Each person is bringing different complementary skill sets to the team. I am looking forward to joining as a scientific advisor to support them on this exciting journey,” says Harsukh Parmar.
Photo of Harsukh Parmar: ISD Immunotech